Latest Capital Management News

Breville Group Limited has announced a fully franked ordinary dividend of AUD 0.19 per share for the six months ending December 2025, signaling steady returns for shareholders.

Breville Group Limited has reported a record half-year revenue of $1.1 billion for the six months ended December 2025, alongside modest profit growth and a raised interim dividend.

Temple & Webster Group Limited reported a robust 20% revenue increase to $376 million in the first half of FY26, maintaining momentum towards its $1 billion revenue target by FY28. The company’s strategic investments in AI, exclusive products, and new markets like New Zealand underpin its expanding market presence.

Northern Star Resources delivers robust half-year financials, confirming the integration of De Grey Mining’s Hemi Project and nearing completion of the KCGM mill expansion.

Northern Star Resources has reported a robust half-year result with a 41% jump in net profit, driven by soaring gold prices despite operational setbacks. The company also declared a fully franked interim dividend of 25 cents per share.

Insurance Australia Group Limited (IAG) has announced a quarterly dividend of AUD 1.5565 per security on its Capital Notes 3, payable mid-March 2026 with partial franking.

Insurance Australia Group Limited has announced a quarterly dividend of AUD 1.6241 per security for its Capital Notes, payable mid-March 2026, reflecting a steady 6.5141% annualised distribution rate.

Insurance Australia Group (IAG) reported a resilient first half of FY26 with an underlying insurance profit of $804 million and maintained its full-year guidance despite integration challenges from the RAC Insurance acquisition.

IAG’s 1H26 results reveal a 35% drop in net profit after tax due to severe weather costs from its RACQI acquisition, yet underlying insurance profit rose 7.6%, supported by solid premium growth and a $200 million share buyback.

Insurance Australia Group’s half year net profit fell 35% to $505 million, weighed down by natural peril claims and integration costs from its RACQI acquisition. Despite this, the insurer maintains its full-year guidance and announces a $200 million share buy-back.

Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.

BKI Investment Company has appointed Morgans Financial to conduct on-market share purchases to fulfill its Dividend Reinvestment Plan obligations, aiming to avoid dilution by pricing shares at no discount.